Literature DB >> 21670602

Scleroderma-like properties of skin from caveolin-1-deficient mice: implications for new treatment strategies in patients with fibrosis and systemic sclerosis.

Remedios Castello-Cros1, Diana Whitaker-Menezes, Alex Molchansky, George Purkins, Louis J Soslowsky, David P Beason, Federica Sotgia, Renato V Iozzo, Michael P Lisanti.   

Abstract

Caveolin-1 (Cav-1), the principal structural component of caveolae, participates in the pathogenesis of several fibrotic diseases, including systemic sclerosis (SSc). Interestingly, affected skin and lung samples from patients with SSc show reduced levels of Cav-1, as compared to normal skin. In addition, restoration of Cav-1 function in skin fibroblasts from SSc patients reversed their pro-fibrotic phenotype. Here, we further investigated whether Cav-1 mice are a useful pre-clinical model for studying the pathogenesis of SSc. For this purpose, we performed quantitative transmission electron microscopy, as well as biochemical and immuno-histochemical analysis, of the skin from Cav-1 (-/-) null mice. Using these complementary approaches, we now show that skin from Cav-1 null mice exhibits many of the same characteristics as SSc skin from patients, including a decrease in collagen fiber diameter, increased tensile strength, and stiffness, as well as mononuclear cell infiltration. Furthermore, an increase in autophagy/mitophagy was observed in the stromal cells of the dermis from Cav-1 (-/-) mice. These findings suggest that changes in cellular energy metabolism (e.g., a shift towards aerobic glycolysis) in these stromal cells may be a survival mechanism in this "hostile" or pro-inflammatory microenvironment. Taken together, our results demonstrate that Cav-1 (-/-) null mice are a valuable new pre-clinical model for studying scleroderma. Most importantly, our results suggest that inhibition of autophagy and/or aerobic glycolysis may represent a new promising therapeutic strategy for halting fibrosis in SSc patients. Finally, Cav-1 (-/-) null mice are also a pre-clinical model for a "lethal" tumor micro-environment, possibly explaining the link between fibrosis, tumor progression, and cancer metastasis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21670602      PMCID: PMC3154363          DOI: 10.4161/cc.10.13.16227

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  45 in total

1.  Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice.

Authors:  M Drab; P Verkade; M Elger; M Kasper; M Lohn; B Lauterbach; J Menne; C Lindschau; F Mende; F C Luft; A Schedl; H Haller; T V Kurzchalia
Journal:  Science       Date:  2001-08-09       Impact factor: 47.728

Review 2.  Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis.

Authors:  Sergio A Jimenez; Chris T Derk
Journal:  Ann Intern Med       Date:  2004-01-06       Impact factor: 25.391

Review 3.  The myofibroblast in wound healing and fibrocontractive diseases.

Authors:  G Gabbiani
Journal:  J Pathol       Date:  2003-07       Impact factor: 7.996

Review 4.  Caveolae: from cell biology to animal physiology.

Authors:  Babak Razani; Scott E Woodman; Michael P Lisanti
Journal:  Pharmacol Rev       Date:  2002-09       Impact factor: 25.468

5.  Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway.

Authors:  P Sambo; S S Baroni; M Luchetti; P Paroncini; S Dusi; G Orlandini; A Gabrielli
Journal:  Arthritis Rheum       Date:  2001-11

6.  Scleroderma and the subcutaneous tissue.

Authors:  R Fleischmajer; V Damiano; A Nedwich
Journal:  Science       Date:  1971-03-12       Impact factor: 47.728

7.  Evaluating the cutaneous involvement in scleroderma: torsional stiffness revisited.

Authors:  L R Knight; J E Smeathers; A H Isdale; P S Helliwell
Journal:  Rheumatology (Oxford)       Date:  2001-02       Impact factor: 7.580

8.  The ultrastructure of skin in progressive systemic sclerosis (scleroderma). I. Dermal collagen fibers.

Authors:  R L Hayes; G P Rodnan
Journal:  Am J Pathol       Date:  1971-06       Impact factor: 4.307

9.  Protocollagen proline hydroxylase activity in the skin of normal human subjects and of patients with scleroderma.

Authors:  J Uitto; J Halme; M Hannuksela; P Peltokallio; K I Kivirikko
Journal:  Scand J Clin Lab Invest       Date:  1969-05       Impact factor: 1.713

10.  Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma.

Authors:  Gabriella Lakos; Shinsuke Takagawa; Shu-Jen Chen; Ahalia M Ferreira; Gangwen Han; Koichi Masuda; Xiao-Jing Wang; Luisa A DiPietro; John Varga
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

View more
  25 in total

1.  Autophagy is a key feature in the pathogenesis of systemic sclerosis.

Authors:  Tracy Frech; Ivana De Domenico; Maureen A Murtaugh; Monica P Revelo; Dean Y Li; Allen D Sawitzke; Stavros Drakos
Journal:  Rheumatol Int       Date:  2013-08-11       Impact factor: 2.631

Review 2.  Fibrosis--a lethal component of systemic sclerosis.

Authors:  Yuen Yee Ho; David Lagares; Andrew M Tager; Mohit Kapoor
Journal:  Nat Rev Rheumatol       Date:  2014-04-22       Impact factor: 20.543

3.  Autophagy and mesenchymal cell fibrogenesis.

Authors:  Moira Hilscher; Virginia Hernandez-Gea; Scott L Friedman
Journal:  Biochim Biophys Acta       Date:  2012-11-09

Review 4.  Caveolin-1 in the Pathogenesis of Diabetic Nephropathy: Potential Therapeutic Target?

Authors:  Richard Van Krieken; Joan C Krepinsky
Journal:  Curr Diab Rep       Date:  2017-03       Impact factor: 4.810

Review 5.  Caveolin-1, cellular senescence and age-related diseases.

Authors:  Huafei Zou; Elena Stoppani; Daniela Volonte; Ferruccio Galbiati
Journal:  Mech Ageing Dev       Date:  2011-11-12       Impact factor: 5.432

6.  Caveolin-1 deficiency protects against mesangial matrix expansion in a mouse model of type 1 diabetic nephropathy.

Authors:  T H Guan; G Chen; B Gao; M R Janssen; L Uttarwar; A J Ingram; J C Krepinsky
Journal:  Diabetologia       Date:  2013-06-21       Impact factor: 10.122

Review 7.  Autophagy: controlling cell fate in rheumatic diseases.

Authors:  Jason S Rockel; Mohit Kapoor
Journal:  Nat Rev Rheumatol       Date:  2016-06-23       Impact factor: 20.543

8.  Interaction of caveolin-1 with ATG12-ATG5 system suppresses autophagy in lung epithelial cells.

Authors:  Zhi-Hua Chen; Jiao-Fei Cao; Jie-Sen Zhou; Hui Liu; Luan-Qing Che; Kenji Mizumura; Wen Li; Augustine M K Choi; Hua-Hao Shen
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-04-11       Impact factor: 5.464

9.  Caveolin-1 is a negative regulator of NADPH oxidase-derived reactive oxygen species.

Authors:  Feng Chen; Scott Barman; Yanfang Yu; Steven Haigh; Yusi Wang; Stephen M Black; Ruslan Rafikov; Huijuan Dou; Zsolt Bagi; Weihong Han; Yunchao Su; David J R Fulton
Journal:  Free Radic Biol Med       Date:  2014-05-14       Impact factor: 7.376

10.  Pharmacological and Genetic Inhibition of Caveolin-1 Promotes Epithelialization and Wound Closure.

Authors:  Ivan Jozic; Andrew P Sawaya; Irena Pastar; Cheyanne R Head; Lulu L Wong; George D Glinos; Tongyu Cao Wikramanayake; Harold Brem; Robert S Kirsner; Marjana Tomic-Canic
Journal:  Mol Ther       Date:  2019-07-30       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.